A Pluridimensional View of Biased Agonism
Author(s) -
Claudio M. CostaNeto,
Lucas T. ParreiraseSilva,
Michel Bouvier
Publication year - 2016
Publication title -
molecular pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.469
H-Index - 198
eISSN - 1521-0111
pISSN - 0026-895X
DOI - 10.1124/mol.116.105940
Subject(s) - functional selectivity , effector , g protein coupled receptor , computational biology , signal transduction , biology , signaling proteins , drug discovery , identification (biology) , receptor , phenotype , subcellular localization , ligand (biochemistry) , agonism , cell signaling , microbiology and biotechnology , neuroscience , bioinformatics , genetics , gene , political science , ecology , cytoplasm , politics , law
When studying G protein-coupled receptor (GPCR) signaling and ligand-biased agonism, at least three dimensional spaces must be considered, as follows: 1) the distinct conformations that can be stabilized by different ligands promoting the engagement of different signaling effectors and accessory regulators; 2) the distinct subcellular trafficking that can be conferred by different ligands, which results in spatially distinct signals; and 3) the differential binding kinetics that maintain the receptor in specific conformation and/or subcellular localization for different periods of time, allowing for the engagement of distinct signaling effector subsets. These three pluridimensional aspects of signaling contribute to different faces of functional selectivity and provide a complex, interconnected way to define the signaling profile of each individual ligand acting at GPCRs. In this review, we discuss how each of these aspects may contribute to the diversity of signaling, but also how they shed light on the complexity of data analyses and interpretation. The impact of phenotype variability as a source of signaling diversity, and the influence of novel and more sensitive assays in the detection and analysis of signaling pluridimensionality, is also discussed. Finally, we discuss perspectives for the use of the concept of pluridimensional signaling in drug discovery, in which we highlight future predictive tools that may facilitate the identification of compounds with optimal therapeutic and safety properties based on the signaling signatures of drug candidates.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom